EXPLORE THE SCIENCE
TL;DR: A 2026 systematic review in The Cochrane Database of Systematic Reviews pooled 17 trials of anti-amyloid monoclonal antibodies (N=20,342 people with mild cognitive impairment or mild Alzheimer’s dementia) and concluded that any effect on memory decline…
Read article
TL;DR: A 2024 Gastroenterology study found that intestinal epithelial serotonin reduced anxiety- and depression-like behavior in mice through vagal signaling, while prenatal SSRI exposure in a human cohort predicted infant functional constipation independent o…
Read article
TL;DR: A 2026 mouse study in iScience found that anesthetic emergence slowed sharply below 31.9°C because two hypothalamic thermoregulatory pathways pushed anesthesia in opposite directions: preoptic BDNF neurons deepened anesthesia, while a dorsomedial-hypoth…
Read article
TL;DR: A 2026 rat study in Psychopharmacology found that THC exposure during late adolescence left adult animals with elevated anxiety-like behavior and impaired object-recognition and spatial-memory performance after a drug-free recovery period. Key Findings…
Read article
TL;DR: A 2026 medRxiv preprint on schizophrenia reported that illness insight tracked with resting-state functional MRI (fMRI) flexibility, a measure of how dynamically brain regions reconfigure their connectivity, and that these brain-dynamics patterns aligne…
Read article
TL;DR: A 2026 study in Nature Neuroscience from Baylor College of Medicine showed that boosting Sox9, a transcription factor that regulates aging astrocytes, improved astrocytes’ ability to clear amyloid plaques in Alzheimer’s mouse models and preserved cognit…
Read article
Gabapentin Plus Hegu Embedding Improved Post-Herpetic Neuralgia TL;DR: Adding weekly Hegu-point catgut embedding to gabapentin cut post-herpetic neuralgia pain and sleep disruption more sharply, raising response from 80.0% to 92.4%. Key Findings 210 randomized…
Read article
Esketamine Lost the Cost-Effectiveness Race in Hong Kong TL;DR: A 5-year Hong Kong model found esketamine plus an antidepressant bought only a small quality-adjusted survival gain at US$29,061 per patient, leaving it behind cheaper third-line options like comb…
Read article
Cannabinoids Had Weak Evidence for Mental Disorders TL;DR: A Lancet Psychiatry review of randomized trials found little support for routine cannabinoid treatment in common mental disorders, despite possible weak signals in a few narrower conditions. Key Findin…
Read article
TL;DR: A 2026 randomized trial in The British Journal of Psychiatry found 6 ketamine infusions improved severe treatment-resistant depression, but curated music added no measurable benefit; higher mystical-experience scores still predicted the next session’s d…
Read article